subject.id	manuscript.id	arm	treatment	crossover.to.ipi.nivo	crossover.day	age	sex	race	ethnicity	tumor.type	tumor.type.abbr	prior.lines.of.therapy	ecog.screening	stage.at.diagnosis	stage.at.enrollment	treatment.duration.months	cd8.percent.baseline	cd8.percent.max.ontrt	best.overall.response	pfs.months	pfs.event.flag	os.months	os.event.flag	responder.flag.crpr	disease.control.flag	cd8.converter.flag	msi	tmb	response_label	tumor.type.tcga
101-0001	1	CD8 LOW	Nivolumab + Ipilimumab			61	F	Other	Not Hispanic or Latino	Pancreatic carcinoma	PANC	3	0.0	Stage 4	Stage 4	1.4127310061601643	6	3.0		4.008213552361396	1	4.008213552361396	1	N	N	N	MSI-L	0.97		PAAD
101-0006	5	CD8 LOW	Nivolumab + Ipilimumab			41	M	White	Not Hispanic or Latino	Pancreatic carcinoma	PANC	4	1.0	Stage 3	Stage 4	1.5770020533880904	12	28.0	Progressive Disease	2.036960985626284	1	5.716632443531828	1	N	N	Y			NR	PAAD
101-0007	6	CD8 LOW	Nivolumab + Ipilimumab			71	F	Other	Not Hispanic or Latino	Non-small cell lung cancer	LUCA	1		Stage 2	Stage 4	2.9568788501026693	1	30.0	Partial Response	13.864476386036962	1	13.9958932238193	0	Y	Y	Y	MSI-L	0.69	R	LUAD
101-0008	7	CD8 LOW	Nivolumab + Ipilimumab			53	F	White	Hispanic or Latino	Ovarian cancer	OVCA	3	1.0	Stage 3	Stage 4	26.87474332648871	11	36.0	Complete Response	11.071868583162216	1	36.63244353182752	0	Y	Y	Y	MSI-Stable	3.5	R	OV
101-0011	9	CD8 LOW	Nivolumab + Ipilimumab			44	F	Other	Not Hispanic or Latino	Breast cancer	BRCA	5+	0.0	Stage 1	Stage 4	2.891170431211499	5	5.0	Progressive Disease	1.9712525667351128	1	3.2525667351129366	0	N	N	N	MSI-Stable	0.45	NR	BRCA
101-0015	11	CD8 LOW	Nivolumab + Ipilimumab			56	F	White	Not Hispanic or Latino	Ovarian cancer	OVCA	5+	1.0	Stage 4	Stage 4	2.4640657084188917	9	21.0	Stable Disease	11.564681724845997	1	11.564681724845997	1	N	N	Y			NR	OV
102-0013	18	CD8 LOW	Nivolumab + Ipilimumab			72	M	White	Not Hispanic or Latino	Sarcoma	SARC	5+	0.0	Stage 4	Stage 4	9.00205338809035	9	35.0	Stable Disease	3.4496919917864477	1	25.100616016427107	1	N	N	Y	MSI-Stable	1.25	NR	SARC
102-0015	19	CD8 LOW	Nivolumab + Ipilimumab			45	F	White	Not Hispanic or Latino	Mixed hepatocellular cholangiocarcinoma	HECH	2	1.0	Stage 4	Stage 4	0.9527720739219712	0	2.0	Stable Disease	1.675564681724846	1	3.811088295687885	1	N	N	N	MSI-Stable	0.8	NR	LIHC
102-0016	20	CD8 LOW	Nivolumab + Ipilimumab			53	M	Black or African American	Not Hispanic or Latino	Sarcoma	SARC	2	1.0	Stage 2	Stage 4	4.402464065708419	1	42.0	Progressive Disease	2.0698151950718686	1	7.62217659137577	1	N	N	Y	MSI-H	1.4	NR	SARC
102-0019	23	CD8 LOW	Nivolumab + Ipilimumab			67	M	White	Not Hispanic or Latino	Prostate cancer	CRPC	5+	1.0	Stage 3	Stage 4	1.4127310061601643	5	38.0	Progressive Disease	2.004106776180698	1	5.355236139630391	1	N	N	Y	MSI-Stable	1.02	NR	PRAD
102-0021	24	CD8 LOW	Nivolumab + Ipilimumab			78	F	Other	Hispanic or Latino	Uterine cancer	UTCA	3	1.0	Stage 1	Stage 4	9.593429158110885	4	22.0	Partial Response	8.673511293634498	1	32.75564681724846	0	Y	Y	Y	MSI-H	16.2	R	UCEC
102-0027	29	CD8 LOW	Nivolumab + Ipilimumab			68	F	White	Not Hispanic or Latino	Uterine cancer	UTCA	5+	1.0	Stage 1	Stage 4	38.96509240246407	1	6.0	Partial Response	39.85215605749487	0	42.87474332648871	0	Y	Y	N	MSI-H	16.64	R	UCEC
102-0033	34	CD8 LOW	Nivolumab + Ipilimumab			72	F	White	Not Hispanic or Latino	Hepatocellular carcinoma	HCCA	5+	1.0	Stage 4	Stage 4	0.7227926078028748	1	0.0	Progressive Disease	2.299794661190965	1	11.203285420944558	1	N	N	N	MSI-Stable	1.75	NR	LIHC
102-0035	35	CD8 LOW	Nivolumab + Ipilimumab			33	M	Other	Hispanic or Latino	Head and neck cancer	HNCA	5+	1.0	Stage 4	Stage 4	2.759753593429158	1	2.0	Progressive Disease	1.9055441478439423	1	3.4496919917864477	0	N	N	N	MSI-L	1.41	NR	HNSC
102-0038	37	CD8 LOW	Nivolumab + Ipilimumab			64	M	White	Not Hispanic or Latino	Head and neck cancer	HNCA	5+	1.0	Stage 4	Stage 4	1.4127310061601643	1	5.0	Stable Disease	2.004106776180698	0	2.3983572895277208	0	N	N	N	MSI-L	3.06	NR	HNSC
102-0042	39	CD8 LOW	Nivolumab + Ipilimumab			55	F	Black or African American	Not Hispanic or Latino	Sarcoma	SARC	2	1.0	Stage 3	Stage 4	0.7227926078028748	1	18.0	Progressive Disease	1.4455852156057496	1	15.835728952772076	1	N	N	Y	MSI-Stable	0.37	NR	SARC
102-0044	75	CD8 HIGH	Nivolumab			55	M	Other	Not Hispanic or Latino	Head and neck cancer	HNCA	4	1.0	Stage 4	Stage 4	3.7782340862423	16	33.0	Stable Disease	3.7125256673511298	0	3.7782340862423	0	N	N		MSI-Stable	4.88	NR	HNSC
103-0001	43	CD8 LOW	Nivolumab + Ipilimumab			32	M	Other	Not Hispanic or Latino	Sarcoma	SARC	5+	0.0		Stage 4	1.6098562628336754	1	1.0	Progressive Disease	0.164271047227926	1	8.870636550308008	1	N	N	N	MSI-Stable	0.62	NR	SARC
103-0003	76	CD8 HIGH	Nivolumab			70	M	White	Not Hispanic or Latino	Gastrooesophageal cancer	GEJC	1	0.0	Stage 1	Stage 4	26.217659137577	22	42.0	Partial Response	9.19917864476386	1	30.12731006160164	0	Y	Y		MSI-Stable	2.83	R	STAD
104-0015	52	CD8 LOW	Nivolumab + Ipilimumab			58	F	White	Not Hispanic or Latino	Thyroid cancer	THYR	4	0.0	Stage 4	Stage 4	5.092402464065708	1	9.0	Stable Disease	5.092402464065708	1	6.669404517453799	0	N	N	N	MSI-Stable	0.33	NR	THCA
104-0020	55	CD8 LOW	Nivolumab + Ipilimumab			80	M	White	Not Hispanic or Latino	Prostate cancer	CRPC	5+	0.0	Stage 2	Stage 4	17.51129363449692	1	1.0	Stable Disease	14.061601642710473	1	27.926078028747437	1	N	Y	N	MSI-Stable	0.7	NR	PRAD
104-0021	56	CD8 LOW	Nivolumab + Ipilimumab			68	M	White	Not Hispanic or Latino	Prostate cancer	CRPC	2	0.0	Stage 4	Stage 4	3.02258726899384	4	16.0	Partial Response	7.523613963039015	0	26.907597535934293	0	Y	Y	Y	MSI-Stable	0.84	R	PRAD
104-0023	58	CD8 LOW	Nivolumab + Ipilimumab			63	F	White	Not Hispanic or Latino	Colorectal cancer	CRCA	2	1.0	Stage 4	Stage 4	0.7227926078028748	0	0.0		4.205338809034908	1	4.205338809034908	1	N	N	N	MSI-L	0.87		COAD
106-0002	62	CD8 LOW	Nivolumab + Ipilimumab			65	M	Other	Hispanic or Latino	Head and neck cancer	HNCA	0	1.0	Stage 3	Stage 4	0.7227926078028748	1	1.0		1.5112936344969197	1	1.5112936344969197	1	N	N	N	MSI-Stable	0.79		HNSC
106-0010	68	CD8 LOW	Nivolumab + Ipilimumab			77	F	White	Not Hispanic or Latino	Ovarian cancer	OVCA	2	1.0	Stage 4	Stage 4	3.9753593429158114	13	28.0	Partial Response	3.9425051334702257	1	28.057494866529773	0	Y	Y	Y	MSI-Stable	1.14	R	OV
